GOSS
Bad news keeps piling up
Gossamer Bio just picked up a securities class action, and it’s not exactly coming out of nowhere. The complaint targets the company and an executive, with investors claiming they were misled between June 16, 2025 and February 20, 2026.
The PROSERA problem
The lawsuit hangs off Gossamer’s February 23 announcement that its Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension missed the primary endpoint. Translation: the late-stage trial didn’t do the one job it was supposed to do, and the market responded by sending the stock into free fall.
Why investors should care
This isn’t just about one bad data readout. The complaint says the real fight is over whether Gossamer was upfront about the trial design, patient recruitment, and site-level monitoring. If that story gains traction, the company could face legal costs, reputational damage, and a longer road to rebuilding trust.
The bigger picture
Biotech is already a roller coaster; add litigation and you’ve got the version with the harness missing. For investors, the headline risk is clear: when a phase 3 miss turns into a securities suit, the pain tends to linger well past the original stock drop. Big picture: this is what happens when science, expectations, and Wall Street all miss the same exit.